Cervical Dystonia Drug Candidate Gets Orphan Drug Designation

DaxibotulinumtoxinA for Injection is currently in development for glabellar lines, cervical dystonia and plantar fasciitis
DaxibotulinumtoxinA for Injection is currently in development for glabellar lines, cervical dystonia and plantar fasciitis

Revance Therapeutics announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to RT002 (daxibotulinumtoxinA for injection) to treat adults with cervical dystonia.

Phase 2 clinical data showed RT002 was safe and well-tolerated while providing a long-lasting improvement of patients' symptoms. Botulinum toxins work by blocking communication between the nerve and muscle, which may alleviate abnormal movements and postures. 

Related Articles

DaxibotulinumtoxinA is being developed for a range of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders; it has the potential to be the first FDA-approved long-acting neuromodulator. Specifically, it is being developed for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis. 

For more information call (510) 742-3400 or visit Revance.com.